
    
      This is an international, multicenter, single arm, prospective, Early Feasibility Clinical
      Study to evaluate the safety and performance of the Neovasc Tiara Mitral Valve System in
      subjects with symptomatic severe mitral regurgitation requiring mitral valve replacement who
      are at high risk for open chest surgery.

      A maximum of 30 subjects will be implanted in this study at a maximum of 10 sites. A maximum
      of 15 subjects will be implanted in the United States.

      Subjects satisfying the inclusion criteria and exclusion criteria will be enrolled to receive
      the Neovasc Tiara Mitral Transcatheter Heart Valve with the Tiara Delivery System via a
      transcatheter mitral valve replacement (TMVR) procedure.
    
  